tirzepatide loss of exclusivity The peptide regulatory landscape in 2026 is in active flux. After the FDA placed 19 popular peptides in Category 2 in late 2023, HHS Secretary RFK Jr. announced in February 2026 that Sandoz files first generic tirzepatide

Short term, they are probably safe, but their long-term use is entirely unclear

All prescriptions require an online medical evaluation with an independent licensed healthcare provider

If any symptom feels severe or persistent beyond 48 hours, contact your healthcare provider immediately

Conclusion Our results suggest that, in a real-world setting, once-weekly injectable GLP-1 RAs are associated with better persistence and adherence than daily regimens over 1 year

In the STEP trials, participants lost an average of 15% of their initial body weight over 68 weeks when combined with lifestyle interventions

Currently, tirzepatide is available only as an injectable medication, known for its effectiveness in managing weight and type 2 diabetes